Topol EJ - Search Results

1

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Vivekananthan DP, et al. Among authors: topol ej. Lancet. 2003 Jun 14;361(9374):2017-23. doi: 10.1016/S0140-6736(03)13637-9. Lancet. 2003. PMID: 12814711

2

Percutaneous revascularization of ostial saphenous vein graft stenoses.

Abdel-Meguid AE, Whitlow PL, Simpfendorfer C, Sapp SK, Franco I, Ellis SG, Topol EJ. Abdel-Meguid AE, et al. Among authors: topol ej. J Am Coll Cardiol. 1995 Oct;26(4):955-60. doi: 10.1016/0735-1097(95)00266-X. J Am Coll Cardiol. 1995. PMID: 7560623 Free article.

3

Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ. Pilote L, et al. Among authors: topol ej. N Engl J Med. 1995 Aug 31;333(9):565-72. doi: 10.1056/NEJM199508313330907. N Engl J Med. 1995. PMID: 7623907 Free article.

4

Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure.

Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Abdelmeguid AE, et al. Among authors: topol ej. Circulation. 1995 Jun 1;91(11):2733-41. doi: 10.1161/01.cir.91.11.2733. Circulation. 1995. PMID: 7758178

5

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, et al. Topol EJ, et al. Lancet. 1994 Apr 9;343(8902):881-6. doi: 10.1016/s0140-6736(94)90007-8. Lancet. 1994. PMID: 7908357 Clinical Trial.

6

Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions.

Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Abdelmeguid AE, et al. Among authors: topol ej. Am Heart J. 1996 Jun;131(6):1097-105. doi: 10.1016/s0002-8703(96)90083-6. Am Heart J. 1996. PMID: 8644587

7

Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions.

Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Abdelmeguid AE, et al. Among authors: topol ej. Circulation. 1996 Oct 1;94(7):1528-36. doi: 10.1161/01.cir.94.7.1528. Circulation. 1996. PMID: 8840840

8

Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial.

Holmes DR Jr, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML, White HD, Thompson TD, Topol EJ. Holmes DR Jr, et al. Among authors: topol ej. Lancet. 1997 Jan 11;349(9045):75-8. doi: 10.1016/s0140-6736(96)03031-0. Lancet. 1997. PMID: 8996417 Clinical Trial.

9

Stenting for acute myocardial infarction.

Steinhubl SR, Topol EJ. Steinhubl SR, et al. Among authors: topol ej. Lancet. 1997 Aug 23;350(9077):532-3. doi: 10.1016/S0140-6736(05)63135-2. Lancet. 1997. PMID: 9284772 No abstract available.

10

Quantitative evaluation of local drug delivery using the InfusaSleeve catheter.

Gottsauner-Wolf M, Jang Y, Penn MS, Kaplan A, Ellis SG, Chisolm GM, Topol EJ, Lincoff AM. Gottsauner-Wolf M, et al. Among authors: topol ej. Cathet Cardiovasc Diagn. 1997 Sep;42(1):102-8. doi: 10.1002/(sici)1097-0304(199709)42:1<102::aid-ccd27>3.0.co;2-r. Cathet Cardiovasc Diagn. 1997. PMID: 9286553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,218 results

Search Page

Filters